Healthcare provider profile · identity verified

Mark A Lutterbie, MD

Family Practice · RICHMOND, VA · NPI 1821201039

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	235	68
Amlodipine Besylate	Amlodipine Besylate	212	63
Metformin Hcl	Metformin Hcl	99	28
Gabapentin	Gabapentin	98	26
Losartan Potassium	Losartan Potassium	91	23
Levothyroxine Sodium	Levothyroxine Sodium	89	26
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	89	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	88	29
Fluticasone Propionate	Fluticasone Propionate	78	22
Lisinopril	Lisinopril	77	23
Hydrochlorothiazide	Hydrochlorothiazide	70	26
Montelukast Sodium	Montelukast Sodium	70	15
Omeprazole	Omeprazole	69	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	67	16
Pantoprazole Sodium	Pantoprazole Sodium	67	19
Oxycodone Hcl	Oxycodone Hcl	60	suppressed
Jardiance	Empagliflozin	55	suppressed
Sertraline Hcl	Sertraline Hcl	55	14
Tramadol Hcl	Tramadol Hcl	54	11
Diclofenac Sodium	Diclofenac Sodium	51	16
Potassium Chloride	Potassium Chloride	50	11
Ibuprofen	Ibuprofen	49	13
Tamsulosin Hcl	Tamsulosin Hcl	49	14
Metoprolol Succinate	Metoprolol Succinate	48	14
Furosemide	Furosemide	47	15
Metformin Hcl Er	Metformin Hcl	44	16
Duloxetine Hcl	Duloxetine Hcl	42	13
Eliquis	Apixaban	41	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	41	suppressed
Baclofen	Baclofen	38	suppressed
Prednisone	Prednisone	38	suppressed
Hydralazine Hcl	Hydralazine Hcl	37	11
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	37	13
Allopurinol	Allopurinol	36	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	35	12
Trazodone Hcl	Trazodone Hcl	35	11
Pregabalin	Pregabalin	33	suppressed
Naproxen	Naproxen	31	12
Lidocaine	Lidocaine	29	suppressed
Ozempic	Semaglutide	29	suppressed
Carvedilol	Carvedilol	28	suppressed
Famotidine	Famotidine	28	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Torsemide	Torsemide	26	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Clonazepam	Clonazepam	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Ondansetron Odt	Ondansetron	24	suppressed
Glipizide Er	Glipizide	23	suppressed
Methadone Hcl	Methadone Hcl	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Glipizide	Glipizide	19	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Valsartan	Valsartan	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Novolog	Insulin Aspart	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Finasteride	Finasteride	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error